rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NBTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Nanobiotix to Participate in Investor Conferences in November
      Nov 9Yahoo FinanceNBTX
      Nanobiotix: The Phase 3 May Come Later, And Lenders Get Paid First (NASDAQ:NBTX)

      Nanobiotix stock hinges on J&J’s JNJ-1900 Phase 3 success, with delayed catalysts and lender claims pressuring upside. Click here to read more on NBTX.

      Oct 30Seeking AlphaNBTX
      Nanobiotix (ENXTPA:NANO) Could Be 46% Undervalued As Melanoma Trial Results Land

      Nanobiotix (ENXTPA:NANO) is back in focus after releasing updated Phase 1 data for JNJ-1900, or NBTXR3, in anti-PD-1-resistant advanced primary cutaneous melanoma treated with radiotherapy plus checkpoint inhibitors. The fresh melanoma data has arrived at a time when Nanobiotix has already seen a sharp swing in sentiment, with a 49.71% 7-day share price return and a 48.53% year-to-date share price return, offset by a weaker 90-day share price return of 14.07% and a very large 3-year total...

      Oct 26Yahoo FinanceNBTX
      Nanobiotix stock gains on positive melanoma trial data
      Oct 26Yahoo FinanceNBTX
      Why is Nanobiotix stock surging today?
      Oct 26Investing.comNBTX
      NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
      Oct 24Yahoo FinanceNBTX
      Voting Rights and Shares Capital of the Company
      Oct 20Yahoo FinanceNBTX
      Nanobiotix (ENXTPA:NANO) Could Be 59% Undervalued After Its CFO Change

      New CFO appointment reshapes Nanobiotix leadership focus Nanobiotix (ENXTPA:NANO) has refreshed its top finance role, naming Arnd Christ as chief financial officer and executive board member after the departure of long-serving executive Bart Van Rhijn. Christ arrives with more than two decades in biotech finance across Europe and the United States, including prior CFO roles at several listed and private drug developers. His background may influence how Nanobiotix approaches funding,...

      Oct 10Yahoo FinanceNBTX
      Nanobiotix Appoints Arnd Christ as CFO
      Oct 1Yahoo FinanceNBTX
      NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer

      PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company’s executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in

      Oct 1Yahoo FinanceNBTX
      Can J&J’s Partnership Drive More Upside for Nanobiotix?
      Sep 28Yahoo FinanceNBTX
      Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and Nanobiotix (NBTX)

      Detailed price information for Damora Therapeutics Inc (DMRA-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailNBTX
      NANOBIOTIX Provides First Half 2026 Operational and Financial Update

      Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiationStrengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029Acceptable safety profile and promising initial efficacy responses obs

      Sep 24Yahoo FinanceNBTX
      Voting Rights and Shares Capital of the Company

      In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisab

      Sep 22Yahoo FinanceNBTX
      Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?

      Nanobiotix S.A. (NASDAQ:NBTX) reported September 14 results from all 24 patients in the dose-escalation and expansion portions of a Phase 1 study of JNJ-1900, also called NBTXR3, combined with repeat radiation. The study enrolled patients with inoperable, locoregionally recurrent non-small cell lung cancer. Nanobiotix S.A. (NASDAQ:NBTX) reported 79% one-year locoregional control at a median follow-up […]

      Sep 17Yahoo FinanceNBTX
      Guggenheim initiates Nanobiotix stock rating at Buy on cancer drug
      Sep 15Investing.comNBTX
      NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

      All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapyInvestigators concluded that JNJ-1900 (

      Sep 14Yahoo FinanceNBTX
      NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

      All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapyInvestigators concluded that JNJ-1900 (

      Sep 13Yahoo FinanceNBTX
      NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

      PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that Company management will participate in a fireside chat at the following investment conference: H.C. Wainwright 28th Annual Global Investment ConferenceDate: Tuesday, September 15, 2026Time: 1

      Sep 9Yahoo FinanceNBTX
      Nanobiotix Joins the Euronext Tech Leaders Index

      PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage...

      Aug 28BarchartNBTX
      Voting Rights and Shares Capital of the Company

      In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2J

      Aug 25Yahoo FinanceNBTX

      This is the newest page. Registered accounts read further back.